TeleVox

A communications and delivery business with a conversational layer on top, and the company is reasonably precise about which is which. The core asset built over decades is the ability to reach patients reliably at scale across text, voice, email and physical mail, together with the workflow content of reminders, recalls, bill pay and refill prompts. That is logistics and clinical content design rather than a model.

The artificial intelligence lives in a named product, Engage, which supplies conversational responses and self service handling and escalates to a person when it cannot proceed. Crediting the precision matters here: the company names the conversational product rather than relabelling the whole platform as artificial intelligence, which is the restraint this index credited to TheraDoc and marked down where others did the opposite. This is the same incumbent shape recorded several times across this session, where a business that predates the current wave adds a model to a distribution position it already held.

Bounded and stated. The conversational product answers patient inquiries, manages appointments and handles routine transactions, and the company describes seamless escalation to live chat as part of the design rather than as an afterthought, so the handoff to a human is a published feature. Nothing clinical is decided.

What is not described anywhere located is the escalation criterion, the handling of a patient who raises a clinical concern during a billing or scheduling conversation, or whether patients are told they are corresponding with a machine, and the last is worth asking of any product operating across text and voice at this scale.

Two retrieval passes located no architecture, no model description, no validation methodology and no accuracy figure. The phrase carrying the technical claim is conversational artificial intelligence, which specifies nothing. One published claim deserves particular scrutiny and is graded on the governance row: company material states that a patient can write in their own language and the system will translate it for the clinician with great accuracy, which is an accuracy claim about clinical translation offered without any evidence.

The substantive material located belongs to a former parent and is a decade old, which is a distinction worth stating as a general rule rather than as a quirk of this record. Securities filings from the corporate owner in the 2011 to 2014 period describe compliance training for healthcare services staff, acknowledge business associate status, and record ongoing data security testing and physical security review at healthcare operation centres.

That is a more explicit account than most vendors publish. It is also not this company's own current statement, it predates two changes of ownership, and no present day retention, minimisation or secondary use position for this product was located.

Disclosure does not survive an ownership change unless the new owner adopts it: the people, the infrastructure, the contracts and the incentives all change, and a filing made by a company that no longer owns the product describes an organisation that no longer runs it. A buyer citing that material in diligence would be relying on assurances nobody currently in the relationship has made.

Nothing else is enumerated either, with no model or model family, hosting arrangement or sub processor list located, and no statement on whether patient interactions inform model development. Ask the current owner for its own position on retention, training use and sub processors, and treat the older material as history rather than evidence.

Two passes located no named customer, no case study identifying an organisation, no peer reviewed publication and no independent evaluation. That is a striking absence for a business of this age and reach, and it likely reflects a company that has never needed to publish because it sells into procurement processes rather than clinical ones.

A revenue figure circulates in a commercial database, but it appears in a summary that database itself labels as machine generated and possibly inaccurate, so it is not relied on here. Nothing located establishes what the conversational product achieves relative to the reminder infrastructure the company already had.

The substantive material found belongs to a former parent and is a decade old, which is a distinction this index has had to draw before. Securities filings from the corporate owner in the 2011 to 2014 period describe HIPAA and health information technology compliance training for healthcare services staff, acknowledge business associate status, and record ongoing data security testing and physical security review at healthcare operation centres.

That is a more explicit account than most vendors publish. It is also not TeleVox's own current statement, it predates two changes of ownership, and no present day retention, minimisation or secondary use position for this product was located. Graded on that basis, and it is the same parent versus product distinction recorded against VigiLanz.

Revised upward on 5 August 2026 on the same finding that corrected this record's security position. The strongest available proxy for a health privacy posture in this segment is an independently validated assessment against a control library built around that rule, and the company holds one at the framework's highest tier, announced in December 2023 for its patient engagement platform, with the company's own security material describing a certified data protection infrastructure across client interactions.

That replaces the earlier reading, which rested on a decade old set of filings belonging to a former parent. Held at B rather than A on three points. The business associate agreement itself and its terms were not located. The certification is scoped to a named product rather than to the company, so which systems it covers should be established rather than assumed.

And the ownership question recorded on this record still bears directly on this axis: a supplier that has passed through several corporate structures, and been through one abandoned sale process, may not hold its agreements or its data in the entity a buyer thinks it is contracting with. Establish the current contracting entity and what happens to the agreement on a change of control.

Corrected on 5 August 2026 after a second retrieval pass located a certification the earlier assessment had missed. The company announced HITRUST risk based two year certification in December 2023, the highest assurance tier that framework offers, with the certifying body's own quality lead quoted in the announcement and the company's information security manager named as its author.

That is an independently validated assessment against a control library that harmonises health privacy, federal and state regulation and several information security standards, and it is a materially stronger credential than the security policies and control descriptions that earn a C elsewhere in this category. Two things hold it at B rather than A, and both are the kind of detail this index has learned to check rather than assume.

The certification names a specific product, the patient engagement platform, rather than the company or the conversational artificial intelligence product assessed on this record, so a buyer should establish which systems sit inside the assessed scope. And the certification is a two year credential announced in December 2023, so on its face it has run its term, and no renewal, no subsequent certification and no trust portal were located. Ask for the current certificate and its scope letter rather than relying on the announcement.

No clearance, authorisation or submission located and none needed. Reminders, scheduling, billing prompts and refill notices are administrative. The regulatory frame that matters is telecommunications rather than device law, since automated outbound contact with patients falls under telephone consumer protection rules that turn on the consent a patient gave to be contacted automatically, and that exposure grows rather than shrinks as a reminder becomes a conversation.

The corporate lineage is unusual in that respect: the former parent was itself a regulated carrier and an emergency services provider, so the organisation has institutional familiarity with communications regulation that most healthcare software vendors lack.

Nothing published, and one specific claim raises a risk the company does not appear to have assessed. Company material states that a patient can write a message in their native language and the system will translate it for their doctor with great accuracy.

Machine translation of clinical communication is a documented source of harm, because errors are not random: they cluster in exactly the constructions patients use to describe symptoms, negation and dosage, and a fluent wrong translation carries no signal that it is wrong. Claiming great accuracy without publishing a measurement, a language list or a human review requirement is the strongest unsupported claim located on this record.

Speech and language performance variation across accent, dialect and first language applies here as it has to eight prior records in this index, and no subgroup analysis, model card or drift monitoring was located.

Two retrieval passes located no architecture, no model description, no validation methodology, no accuracy figure and no warranty, indemnity or remediation commitment. The phrase carrying the technical claim specifies nothing. One published claim deserves particular scrutiny and it is the sharpest thing on this record.

Company material states that a patient can write in their own language and the system will translate it for the clinician with great accuracy, which is an accuracy claim about clinical translation offered without any evidence at all.

Clinical translation is a domain with a well documented harm literature, where a mistranslated symptom, negation or medication instruction has produced serious consequences, and where professional interpreters exist precisely because the failure modes are subtle rather than obvious.

An unquantified assurance of great accuracy in that setting is worse than silence for the reason this index has recorded elsewhere: a clinician told the translation is accurate has no reason to seek an interpreter for the message they cannot read, so the claim removes the mitigation. Nothing states which languages are supported, how translation quality was assessed, or what the system does when confidence is low. Ask for the language list, the evaluation method and results per language, and what a clinician is shown about translation uncertainty.

Integration is central to the pitch and unevidenced in the particulars. The enterprise product is described as unifying the call centre, the record system, the customer relationship system and other digital health applications into one channel to the patient, and the company states that built in integrations drive scheduling, reminder and billing messages without staff intervention, which is the right design and is the reason a delivery platform becomes useful rather than merely noisy. Two passes located no named record system, no interoperability standard and no implementation detail. Graded C on what is verifiable rather than on the strength of the description.

Two passes located no architecture description, hosting region, residency commitment or deployment option. A hosted service is implied by the nature of an outbound messaging platform, and nothing beyond that inference is published. For a supplier transmitting patient communication across text, voice, email and physical mail, the question of where message content and patient contact data are held, and for how long after a message is sent, is basic and unanswered.

No pricing, pricing mechanism or basis of charge published, with third party coverage recording only that quotes are custom. The more consequential commercial fact concerns the supplier rather than the price. The business has passed through a corporate acquisition in 2007, a corporate rebranding, a private equity take private in 2017, a further group renaming, and in February 2024 its owner appointed banks to explore selling TeleVox specifically.

That process appears not to have resulted in a sale. Current material from a sibling brand states that the president of WestCX oversees both the Mosaicx and TeleVox brands within West Technology Group, having joined in 2025, which indicates TeleVox was retained and grouped with a sibling conversational artificial intelligence product rather than divested.

No announcement confirming the outcome was located, so the position is inferred from the sibling's own material rather than stated by the owner. A health system contracting here should still establish who the contracting entity is, what happens to agreements on a change of control, and where patient data sits through any future transaction, because a business that has been through four ownership or structural changes and one abandoned sale process is more likely than most to go through another.

Broad across organisation type, channel and function, which is what a delivery platform accumulates over decades. Customers span hospitals and health systems, medical practices, and dental and vision practices, which is a wider range of buyer size than most vendors in this index serve.

Channels cover text, voice, email and physical mail, and retaining postal delivery is not a legacy oddity but a genuine reach advantage for older and rural populations that digital only platforms miss entirely. Functionally it runs from appointment reminders and recalls through scheduling, bill pay, prescription refills, broadcast messaging, discharge instructions and post discharge symptom check ins. Not tied to a clinical specialty. Geography is the United States. Held at B rather than A because none of the breadth is evidenced by a named deployment.